Dasatinib and quercetin human research
MASH proof-of-principle result published
A small placebo-controlled trial reported a liver histology result.
Research development record
The dates below describe the events and disclosures. Sources were checked for this edition on 4 October 2026.
40 developments
ER-100
Interim presentation scheduled
Company announcement schedules a glaucoma-cohort presentation for 8 October, after this dossier's verification date.
Rentosertib
Phase 3 first dosing announced
Insilico reports the start of dosing in GENESIS-IPF-3, identified as NCT07687459.
Rentosertib
Ageing-clock analysis published
Ancillary analysis asks what proteomic changes in the existing trial indicate about ageing biology.
EGEN-2784 engineered pig kidney
Expanded-access update released
Company described expanded-access outcomes and revised study timing.
Sources: Expanded-access clinical update
XPRIZE Healthspan measurement and trials
Twenty finalists announced
Ten finalists received milestone awards; all twenty advanced.
NewLimit epigenetic reprogramming
Manufacturing and model work updated
Company describes late preclinical preparation and extension of AI prediction across cell types.
Sources: 2026 May/June progress update
ER-100
First participant dosed
Life Biosciences announced the first administration in its Phase 1 trial.
NewLimit epigenetic reprogramming
2027 trial intention disclosed
Financing announcement says NewLimit plans its first reprogramming medicine's human study next year.
Liver mRNA immune restoration
Supplementary table corrected
Duplicated Supplementary Table 3 replaced; the publisher records the correction.
RJB-0402 liver-directed FGF21 gene therapy
PKP2 model paper published online
The FGF21 vector study reported cardiac and calcium findings in mice.
Liver mRNA immune restoration
Journal issue published
Nature includes the earlier online paper in its February issue.
Sources: Nature, Volume 650, Issue 8101
ER-100
IND clearance announced
The company announced FDA clearance to begin ER-100 human testing. Clearance to test is distinct from approval to market a treatment.
XPRIZE Healthspan measurement and trials
Guidelines version 2.2 released
Revised competition rules increased the upper participant age limit to 90.
Liver mRNA immune restoration
Study published online
The primary experimental report becomes available.
Senolytic CAR T cells
Intestinal study published online
A further mouse study examines tissue regeneration; the journal issue is January 2026.
Shift cellular rejuvenation
Virtual-cell metric work announced
Shift describes work on calibrating how genetic-perturbation prediction models are evaluated.
Sources: Shift Bioscience research news
EGEN-2784 engineered pig kidney
Human physiology paper published
A case report described the first recipient's kidney function.
EGEN-2784 engineered pig kidney
Trial permission announced
eGenesis reported FDA clearance for a formal kidney study.
Retro cellular reprogramming
Engineered factors disclosed
OpenAI and Retro report their model-to-laboratory protein-engineering work.
UBX1325 / foselutoclax
Operating programme wound down
The board approved seeking dissolution and the company closed out ASPIRE.
Shift cellular rejuvenation
SB000 preprint posted
Laboratory manuscript reports single-factor molecular rejuvenation experiments.
Rentosertib
Phase 2a results published
Nature Medicine reports the 71-participant randomised IPF study.
XPRIZE Healthspan measurement and trials
First milestone awards announced
Forty Healthspan teams were selected as milestone winners from the earlier qualifying cohort.
Sources: First milestone winners announced
UBX1325 / foselutoclax
Complete ASPIRE results disclosed
Week-36 findings were reported alongside the missed primary time-window comparison and strategic review.
LYG-LIV-001 ectopic liver tissue
First cohort passed safety review
Company reported the board's recommendation to continue and escalate.
NewLimit epigenetic reprogramming
Preclinical progress reviewed
Company year-in-review reports transcription-factor discoveries and animal liver-disease work.
Sources: 2024 year in review
ER-100
Primate data disclosed
Life Biosciences reported further NAION-like injury-model results at AAO.
Dasatinib and quercetin human research
Bone primary endpoint missed
The randomised trial added a negative primary result.
LYG-LIV-001 ectopic liver tissue
First participant reported dosed
LyGenesis announced the start of human dosing.
Rentosertib
Discovery and early testing published
Nature Biotechnology documents AI-assisted target selection and molecular generation alongside experimental validation.
Senolytic CAR T cells
Metabolic study published
Research extends the approach into natural-ageing and preventive mouse experiments.
EGEN-2784 engineered pig kidney
Engineered donor paper published
Nature paper documented donor edits and nonhuman-primate testing.
NewLimit epigenetic reprogramming
Platform approach described
NewLimit explains its combination of single-cell genomics, pooled screens and machine learning.
Sources: Developing reprogramming therapies
ER-100
Mouse vision study published
OSK research connected molecular reprogramming with retinal function in experimental mice.
LYG-LIV-001 ectopic liver tissue
Swine evidence published online
The paper described ectopic liver tissue after hepatocyte transplantation.
Senolytic CAR T cells
uPAR-targeting foundation published
Cell and mouse experiments establish the senolytic CAR T approach.
Dasatinib and quercetin human research
Human tissue pilot published
Researchers reported changes in senescence-associated markers.
Altos cellular rejuvenation
Partial-reprogramming foundation published
Academic experiments later cited by Altos test brief reprogramming in cells and mouse models.
Dasatinib and quercetin human research
Drug discovery paper published
Cell and animal experiments established the combination's research rationale.
No developments match this field.